Insights on the Irritable Bowel Syndrome (IBS) Treatment Market to 2028 | The Insight Partners

1
Irritable Bowel Syndrome (IBS) Treatment Market
Global Analysis and Forecast to 2028

• Published Date May 2021

Email sales_at_theinsightpartners.com
2
Report Studies
Email sales_at_theinsightpartners.com

• Irritable Bowel Syndrome (IBS) Treatment Market
  Forecast to 2028 - COVID-19 Impact and Global
  Analysis By Type IBS with Diarrhea (IBS-D), IBS
  with Constipation (IBS-C), and Mixed IBS
  (IBS-M), Product (Rifaximin, Eluxadoline,
  Lubiprostone, Linaclotide, and Others), and
  Distribution Channel (Hospital Pharmacies, Drug
  Stores and Retail Pharmacies, and Online
  Pharmacies)

3
Irritable Bowel Syndrome (IBS) Treatment Market
Overview
Email sales_at_theinsightpartners.com

• The Irritable Bowel Syndrome (IBS) Treatment
  Market was valued at US 2,153.89 million in 2020
  and is projected to reach US 4,600.30 million by
  2028 it is expected to grow at a CAGR of 10.1
  from 2021 to 2028.
• The major factors such as the increasing
  prevalence of irritable bowel syndrome diseases
  and rising research development activities
  drive the market growth. However, the limited
  number of product availability and treatment
  inefficiency restrain the market growth. IBS is a
  common chronic condition that affects the
  abdominal organ, large intestine. It is also
  known as spastic colon, mucous colitis, irritable
  colon, and spastic colitis. The condition is much
  different than inflammatory bowel disease. It
  shows symptoms such as cramping, abdominal pain,
  bloating, gas, and diarrhea or constipation, or
  both at the same. If the symptoms are mild, they
  can be managed by changing stress, lifestyle, and
  diet. On the other side, severe symptoms are
  treated with medication and counseling.

4
Key Segment Market
Email sales_at_theinsightpartners.com

• Segment By Type-
• By Type (IBS with Diarrhea (IBS-D), IBS with
  Constipation (IBS-C), and Mixed IBS (IBS-M))
• Product (Rifaximin, Eluxadoline, Lubiprostone,
  Linaclotide, and Others)
• End-User (Hospital Pharmacies, Drug Stores and
  Retail Pharmacies, and Online Pharmacies)

Download Sample Here
5
Irritable Bowel Syndrome (IBS) Treatment Market
Value
Email sales_at_theinsightpartners.com

• CAGR of 10.1
• (2021 - 2028)

Download Sample
6
Company Profiles
Email sales_at_theinsightpartners.com

• Ironwood Pharmaceuticals, Inc.
• AbbVie.
• Sebela Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Alfasigma S.p.A.
• Astellas Pharma Inc.
• AstraZeneca
• Synthetic Biologics, Inc.
• Bausch Lomb Incorporated
• Lannett Company Inc

Download Sample Here
7
By Geography
Email sales_at_theinsightpartners.com

• North America (the US, Canada, and Mexico)
• Europe (the UK, Germany, France, Italy, Spain,
  and the Rest of Europe)
• Asia Pacific (China, Japan, India, Australia,
  South Korea, and the Rest of Asia Pacific)
• Middle East Africa (the UAE, Saudi Arabia,
  South Africa, and the Rest of Middle East
  Africa)
• South Central America (Brazil, Argentina, and
  the Rest of South Central America).

8
THANKYOU!

• Phone  [phone]

• E-Mail sales_at_theinsightpartners.com